2.3. OncoTherad
DISEASE
None of the investigated patients experienced disease relapse during initial follow-up (from 1 to 6 months) after OncoTheradFurthermore, based on the comparison between outcomes observed for OncoTheradWith respect to histological staging and grading after OncoTheradLikewise, OncoTheradIn total, 32 patients (72.7%) subjected to OncoTherad